Argo Biopharma Secures Multi-Asset License and Option Deals with Novartis for Cardiovascular Drug Candidates

Argo Biopharmaceutical Co., Ltd., a clinical-stage biotech focused on next-generation siRNA therapies, has announced a new strategic collaboration with Novartis to develop multiple cardiovascular assets from Argo’s pipeline. This marks the third transaction between the two companies, further strengthening their partnership in cardiovascular, renal, and metabolic disease areas.

Dr. Dongxu Shu, CEO of Argo Biopharma, highlighted that the deal supports the company’s ambition to become a global biotech leader by advancing innovative siRNA therapeutics and expanding its clinical development capabilities worldwide.

Novartis’ Dr. Shaun Coughlin, Global Head of Cardiovascular and Metabolism, emphasized the promise of long-acting siRNAs for cardiovascular disease prevention and treatment, expressing enthusiasm to build on their existing collaboration with Argo.

Key elements of the new agreements include:

• Novartis gaining an option to license ex-China rights to two discovery-stage molecules targeting severe hypertriglyceridemia and mixed dyslipidemia, along with a right of first negotiation for BW-00112 (ANGPTL3), currently in Phase II trials in the U.S. and China.
• A license with reciprocal profit and loss (P&L) options for an additional hepatic-delivered siRNA candidate entering Phase I trials in 2026, allowing Novartis ex-China rights and P&L options in China, and vice versa for Argo in the U.S.

Under the terms, Argo will receive an upfront payment of $160 million and could earn up to $5.2 billion in milestone and option payments, plus tiered royalties on sales. Novartis also expressed interest in participating in Argo’s next equity financing round.

Cardiovascular disease remains a leading global cause of death, and siRNA therapeutics offer a novel approach with improved efficacy and dosing profiles. Argo leverages a global discovery and development strategy across Asia, the U.S., and Europe to deliver differentiated treatments for patients in need.

BofA Securities acted as Argo Biopharma’s financial advisor for the deal.